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ABSTRACT 
B cell depleting therapy has proven to be an effective treatment in 
rheumatoid arthritis (RA), a disease characterized by the presence of 
autoantibodies against citrullinated proteins (ACPA) and the Fc portion of 
IgG (rheumatoid factor, RF). This demonstrates the vital role B cells play in 
the disease. The aim of this thesis was to explore the role of B cell 
subpopulations in the pathogenesis of RA. Our interest in a specific B cell 
population arose with the discovery of murine autoreactive B cells, CD21-/low 
cells, which expressed low surface levels or lacked the complement receptor 
2 (CD21). CD21 helps activate B cells, as it is a part of the B cell co-receptor 
complex.  
In Studies I-III we analyzed B cell populations in human peripheral blood 
with the help of flow cytometry utilizing multiple cell markers. In Studies II-
III, clinical as well as radiographic data was collected from RA patients.  
In Study I we established that CD21-/low B cells are found in human 
peripheral blood and discovered that in healthy donors (HDs) this B cell 
population is mainly composed of memory B cells (MBCs) based on their 
phenotype and response to combined stimuli. In Study II we compared the B 
cell populations in peripheral blood of patients with established RA and HDs. 
We saw a higher proportion of a CD21-/low subpopulation, i.e. CD21-/low 
CD27-IgD- (double negative, DN) in patients with autoantibodies (ACPA/RF) 
compared to HDs. Additionally, the frequency of CD21-/low DN cells was 
higher in ACPA/RF positive patients with more joint destruction compared to 
those with less, and the CD21-/low DN population correlated positively with 
the level of destruction. The CD21-/low DN population was highly enriched in 
the inflamed joints of RA patients and a third of the cells expressed RANKL, 
which stimulates osteoclastogenesis. In Study III, we compared the B cell 
populations in peripheral blood in newly diagnosed untreated RA patients 
and HDs. We observed that the proportion of CD21+CD27+ MBCs correlated 
positively with RF and ACPA titers. In addition, the frequency of CD21+ DN 
cells and CD21-/low DN MBCs correlated positively with tender joint count 
and joint narrowing score respectively. 
In conclusion, it seems that different MBCs have different roles in RA where 
CD21+ CD27+ MBCs appear to drive the autoantibody response, the 
CD21+DN MBCs the joint inflammation and the CD21-/low DN MBCs the 
joint damage.  
 SAMMANFATTNING PÅ SVENSKA 
B celler är en viktig del av vårt immunförsvar och kännetecknas av deras 
förmåga att producera antikroppar. Vid den autoimmuna ledsjukdomen 
reumatoid artrit (RA) har immunsystemet av okänd anledning börjat attackera 
lederna och ca 50-70% av patienterna har specifika antikroppar riktade mot 
egna vävnader, så kallade autoantikroppar. Terapi riktad mot B celler ger bra 
resultat i denna patientgrupp. Detta indikerar att B cellerna spelar en 
betydande roll vid RA.  
Syftet med doktorandprojektet är att studera förekomst av olika 
subpopulationer av B celler hos patienter i samband med insjuknande i RA 
och under sjukdomsförloppet, samt att se om det finns samband mellan 
specifika B cells subpopulationer och kliniska symptom. I alla studierna 
användes flödescytometri för att analysera B cells subpopulationer med hjälp 
av flera cellmarkörer. Dessutom analyserades autoantikroppar (ACPA, RF), 
allmänna inflammationsmarkörer (SR, CRP), DAS28 och röntgen av händer 
och fötter i Studier II-III. 
Tidigare hade man hos möss hittat en autoreaktiv B cells population som 
uttryckte lite eller helt saknade komplement receptor 2, CD21, på ytan 
(CD21-/low celler). CD21 är en viktig del av B cellens s.k. co-receptor 
komplex vilket påverkar aktiveringen av cellen. Vi ville studera CD21-/low 
celler hos friska människor samt RA patienter.  
I Studie I påvisade vi CD21-/low celler i friska människor, och dessa celler 
liknade den tidigare beskrivna B cellspopulationen i möss. Största delen av 
dessa celler var minnesceller som indikerade att de inte behövde lika mycket 
stimulering som omogna celler för att aktiveras och deras respons var större. I 
Studie II jämförde vi B celler i friska kontroller och patienter med långvarig 
RA. RA patienter med autoantikroppar (ACPA, RF) hade en ökning av en 
subpopulation av CD21-/low celler som saknade både CD27 och IgD, därför 
kallade double negativa, DN. Andelen CD21-/low DN celler var högre i 
ACPA/RF positiva patienter med ökad leddestruktion jämfört med patienter 
med mindre. CD21-/low DN korrelerade också positivt med graden av 
leddestruktion i ACPA/RF positiva patienter. Dessutom utgjorde de en stor 
andel av B cellerna i ledvätska från RA patienter, där de uttryckte RANKL 
som stimulerar genes av osteoklaster, dvs. de celler som bryter ner ben. I 
Studie III jämförde vi B cells populationer i friska kontroller och patienter 
med nydiagnostiserad och obehandlad RA. Minnesceller som var CD21+ och 
uttryckte CD27+ korrelerade positivt med nivåer av autoantikroppar i blodet 
och CD21+ DN minnesceller korrelerade positivt med antalet ömma leder. I 
likhet med Studie II hittade vi ett samband mellan CD21-/low DN cellerna och 
leddestruktion. CD21-/low DN cellerna korrelerade positivt med graden av 
broskdestruktion.  
Sammanfattningsvis har olika typer av minnesceller olika roller i RA, där 
CD21+ CD27+ celler verkar kopplade till autoantikroppstitrar, CD21+ DN till 
ledinflammation och CD21-/low DN subpopulationen till leddestruktion. 
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ABBREVIATIONS 
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NSAID Nonsteroidal anti-inflammatory drug 
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PGA Patient global assessment 
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SLC Surrogate light chain 
SLE Systemic lupus erythematosus 
SLO Secondary lymphoid organ 
TJC Tender joint count 
TNF Tumor necrosis factor 
TLR Toll-like receptor 
tsDMARD Targeted synthetic disease-modifying antirheumatic drug 
ueRA Untreated early RA 
 
Katrin Thorarinsdottir 
 7 
1 INTRODUCTION 
"The most disturbing yet revealing instance of the body's betrayal of itself is 
autoimmune disease," reflected Mark C. Taylor, a theologian, suffering from 
diabetes mellitus 1. In fact, all through the first half of the 20th century the 
idea of autoimmunity was considered so serious and impossible that it wasn't 
accepted until in the 1950's. The concept of autoimmunity was also what 
sparked my interest in rheumatology. Autoimmunity remains an enigma for 
rheumatologists as can be seen in rheumatoid arthritis (RA). Daily we treat 
patients with RA and despite great progress in diagnosis and treatment we 
still can't fully explain why our patients develop the disease. Further research 
on pathogenesis and unveiling of disease mechanism is vital as with better 
understanding, the treatment targets become clearer leading to better choice 
of medication for the individual patient as well as new ideas for therapy or 
prevention. With the new age of biologic therapy, B cells have become a 
treatment target in many autoimmune diseases including RA. In this thesis 
my aim was to further investigate the role of B cells in the pathogenesis of 
RA.  
1.1 RHEUMATOID ARTHRITIS 
1.1.1 EPIDEMIOLOGY 
One of the first descriptions of RA is from 1676 where Thomas Sydenham 
described a joint disease that differed from gout 2. He described many 
features of the disease including its periodicity, hand deformities, disability 
and chronicity: "it will last for months and years; nay, it will torment a 
patient throughout his miserable time." 2 However, the modern term 
rheumatoid arthritis was not coined until 1859 by Alfred Baring Garrod, a 
physician at the West London Hospital. Until that time the disease had often 
been called rheumatic gout 2, 3. RA is a chronic autoimmune disease that 
primarily involves the joints with a prevalence around 0.5-1%. The highest 
reported prevalence is in native American-Indian populations, around 5-7% 
and one of the lowest in rural Africa 4, 5. There is a higher incidence in 
northern (20-50/100.000/year) compared to southern European countries (9-
24/100.000/year) 5, 6. Similar to many other autoimmune diseases, RA is 
more common in women (female to male ratio 3:1) 5, 7. The patient can 
develop RA at any age with a peak incidence around the fifth decade of life 
although some more recent studies have suggested a later onset 5, 8. 
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1.1.2 ETIOLOGY  
1.1.2.1 GENETIC HOST FACTORS 
The etiology of RA is not completely understood but it is thought to be the 
result of a complex interplay between genetic and non-genetic host factors as 
well as environmental factors (Figure 1). Twin studies have revealed that 
around 50-60% of disease occurrences can be explained by genetic factors 4. 
In the 1970s it was described that 70% of the RA patients carried a specific 
major histocompatibility complex (MHC) class II, i.e. Human leukocyte 
antigen (HLA)-DR4, compared to 30% of the controls. With further research 
it was discovered that the alleles of HLA-DR that carried the highest risk 
shared a common amino acid sequence (70-74) in the third hypervariable 
region of the DRβ chain which was called the shared epitope (SE) 9. SE has 
been shown to have greater affinity for citrullinated compared to native self-
peptides 10 and it is also associated with the presence of autoantibodies 
against citrullinated peptides (ACPA) 11. This suggests that the SE plays a 
role in the activation of the adaptive immune response against citrullinated 
peptides. Citrullination i.e. the post-translational modification of arginine to 
citrulline, is not specific to RA but occurs during inflammation, endoplasmic 
reticulum stress and autophagy 12, 13. Around 50-70% of RA patients present 
with serum autoantibodies, i.e. ACPA and/or autoantibodies against the Fc 
portion of IgG (rheumatoid factor, RF). The heritability of RA in these 
patients (seropositive) is around 40-65% whereas in patients without 
autoantibodies (seronegative) it is around 20% 14. HLA genes explain around 
40% of the genetic risk while the contribution of non-HLA genes is 
considerably smaller (5%) 15. Among the non-HLA genes, the PTPN22 has 
one of the strongest risk associations with RA where polymorphisms in the 
gene is proposed to alter the threshold for activation in immune cells 15. 
1.1.2.2 NON-GENETIC HOST FACTORS 
The female to male ratio of 3:1 seen in RA is in line with other autoimmune 
diseases where women usually have an increased risk compared to men. 
Around 80% of patients with autoimmune diseases are women. The reason 
for this bias is not fully understood but sex hormones and sex chromosomes 
are thought to play a role 16. Focus has been on the sex hormones that greatly 
influence the immune system e.g. tolerance mechanisms by impairing 
negative selection of autoreactive B cells 16. The risk of RA is decreased 
during pregnancy and it is thought to be due to high levels of the immune 
suppressive hormone progesterone 16. Regulation of immune responses via 
estrogen is more complicated as the levels of estrogen vary greatly through a 
woman's lifetime and the levels have contrasting effects with low and high 
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levels inducing a Th1 and Th2 response respectively 16. How much the sex 
chromosomes contribute to the pathogenesis of RA is unclear. Women have 
two X chromosomes where the one is inactivated. However, the inactivation 
is often incomplete resulting in overexpression of genes 17. Skewed silencing 
of X chromosome is more common in autoimmune diseases including RA 
but could be a consequence rather than a cause of disease 18, 19. 
 
Figure 1. A general model of RA development: RA arises in a genetically 
susceptible individual after multiple non-genetic triggers (e.g. infections, sex 
hormones, smoking, exposure to silica) where at least one trigger induces post-
translational modifications of proteins e.g. citrullination, which in turn activates 
an autoreactive immune system. The lightning symbolizes the multiple triggers by 
non-genetic factors needed for the development of RA. The nature of each "hit", 
when they occur and number needed is unknown. Pre-RA is when patient has 
autoantibodies and arthralgia (joint pain) but no arthritis (swollen joint).  
1.1.2.3 ENVIRONMENTAL FACTORS 
Smoking is the largest known environmental risk factor for RA and is 
estimated to account for around 20% of the total environmental risk 20. The 
combination of smoking and two alleles of SE increases the risk of 
developing seropositive RA 21-fold compared to non-smokers carrying no 
SE genes 21. There are also other agents affecting the lungs that can trigger 
ACPA positive RA 22 such as silica 23 and textile dust 24, 25. Similar to 
smoking the combination of exposure to these irritants and being a carrier of 
SE greatly increases the risk of developing RA 25. Other environmental 
factors, such as poor socioeconomic status 8 and infections have also been 
associated with the development of the disease 26. An infectious trigger has 
long been suspected with candidate pathogens varying from Proteus 
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mirabilis 27 and Epstein-Barr virus26, 28. Other candidate pathogens are the 
bacteria found in periodontal disease, Porphyromonas gingivalis and 
Aggregatibacter actinomycetemcomitans, which could promote RA via their 
citrullination of peptides 15, 29. However, a causal relationship between 
infection and RA has not been proven. 
1.1.3 PATHOGENESIS 
As mentioned above, around 50-70% of RA patients have autoantibodies 
specific for disease (RF and ACPA) and their presence is associated with 
more severe symptoms and joint damage 26. These autoantibodies can appear 
up to at least 10 years before the debut of joint symptoms 30 but not all 
individuals with ACPA develop RA. Only around 20-40% of patients with 
arthralgia and autoantibodies, progress to RA within 2 years 31. Taken 
together this implies that a breach of tolerance happens long before disease 
onset and that autoantibodies per se are not enough to cause disease, an 
additional trigger is needed.  However what is also known is that the epitope 
diversity and concentration of ACPA increase over time suggesting that there 
is a progressive loss of tolerance 9.  
The starting point of RA has been theorized to be in the lungs, as we know 
that smoking is a strong environmental risk factor. Supporting this is the 
presence of citrullinated peptides in the lungs in addition to increased levels 
of ACPA in bronchoalveolar lavage fluid compared to sera of ACPA positive 
patients suggesting local production of ACPA in the lungs 25, 32. Another 
theory is that RA starts in the gums with the peptide-citrullinating bacteria 
i.e. P. gingivalis or A. actinomycetemcomitans acting as the main culprits 22. 
Irrespective of the initial trigger and its localization it is thought that the 
modified peptide, now considered a foreign antigen, is carried to a secondary 
lymphoid organ (SLO) where B and T-cells are activated and autoantibodies 
are produced e.g. ACPA. ACPA can be pathogenic either directly by binding 
citrullinated epitopes and activating macrophages and/or osteoclasts 33, 34 or 
indirectly by acting through immune complexes binding to Fcγ receptors 35. 
Ectopic lymphoid structures comprised of T and B cells, including ACPA 
positive B cells, appear in the synovium 9, 36, 37. The thickness of the 
synovium expands where there is an accumulation of innate and adaptive 
immune cells as well as macrophages and activated fibroblasts 9. This 
synovial tissue has been described as tumor-like as it infiltrates and erodes 
cartilage and bone 38. Destruction of cartilage is mediated by matrix 
metalloproteinases and other enzymes secreted mainly by synovial 
fibroblasts. However, the degradation of bone is the work of osteoclasts, 
emerging from pre-osteoclasts stimulated by factors that e.g. act via receptor 
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activator of nuclear factor kappa-β (RANK) 9. Its ligand, RANKL, (also 
known as osteoclast differentiation factor), is secreted or expressed on the 
surface of fibroblasts, T and B cells. The final result is chronic inflammation 
and destruction of multiple joints 26. 
1.1.4 CLINICAL MANIFESTATIONS 
The typical RA patient has an insidious onset of morning stiffness (lasting 
more than 1 hour) and swollen and tender joints as well as an increase in 
inflammatory markers such as erythrocyte sedimentation rate (ESR) and C-
reactive protein (CRP) 26, 39, 40. The disease typically is polyarticular (>4 joints 
simultaneously) affecting the small joints of the hand and feet in a 
symmetrical fashion 41. The clinical picture varies greatly with some patients 
having mild disease to other having severe disease with multisystem 
inflammation 38. Patients commonly have secondary Sjögren's syndrome 
(dryness in eyes and mouth) and rheumatoid nodules 42. Disease activity and 
smoking are risk factors for severe extra-articular manifestations such as 
interstitial lung disease, vasculitis and neuropathy. These severe organ 
manifestation occur less frequently nowadays with better treatments 42. In 
addition, RA patients have a higher prevalence of several comorbidities such 
as cardiovascular disease, infections, osteoporosis and lymphoma, which is in 
large part due to inflammation and also, e.g. for osteoporosis and infections 
in some part due to treatment 43, 44. The higher risk of mortality in RA is 
largely explained by its comorbidities 45. 
1.1.5 DIAGNOSIS AND DISEASE ACTIVITY 
There is no single test that results in the diagnosis of RA. Rather, the 
diagnosis is based on a combination of clinical findings, laboratory results 
including immunological tests and radiographic hallmarks of RA. As the 
symptoms can overlap considerably with that of other rheumatic diseases an 
accurate diagnosis can be difficult to make. The classification criteria for RA 
from 1987 and 2010 are often used as tools to help in the diagnosis of RA. 
However, the criteria do not replace the rheumatologist's clinical knowledge, 
as the criteria were not developed for the purpose of diagnosis but for studies 
so that the study groups would be as homogenous as possible 40.  
1.1.5.1 CLASSIFICATION OF RA 
In 1987 a committee of the American Rheumatism Association revised the 
classification criteria for RA which are still in use (Table 1) 46. However, 
with increasingly more effective treatments for RA it became important to 
make the diagnosis earlier in the disease process before irreversible damage 
occurred. Unfortunately, the 1987 American College of Rheumatology 
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(ACR) criteria had low sensitivity and specificity for diagnosing patients with 
early RA and new classification criteria were devised in 2010, 
ACR/European League Against Rheumatism (EULAR) 2010 criteria (Table 
2) 26.  
 The 1987 ACR criteria  Table 1.
1. Morning stiffness (at least 1 hour) 
2. Arthritis of ≥3 joint areas (PIP, MCP, wrist, elbow, knee, ankle and MTP 
joints) 
3. Arthritis of hand joints (≥1 swollen joints) (PIP, MCP or wrist) 
4. Symmetrical arthritis 
5. Rheumatoid nodules 
6. Serum RF 
7. Radiographic changes (hand or wrist) 
Patients fulfilling at least 4/7 criteria are classified as having RA. Criteria 1-4 must have been 
present for at least 6 weeks. PIP, proximal interphalangeal; MCP, metacarpophalangeal; MTP, 
metatarsophalangeal. 
 
 The 2010 ACR/EULAR criteria  Table 2.
1. Joint involvement (0-5) 
- 1 large joint (0) 
- 2-10 large joints (1) 
- 1-3 small joints (large joints not counted) (2) 
- 4-10 small joints (large joints not counted) (3) 
- >10 joints (at least 1 small joint) (5) 
2. Serology (0-3) 
- Negative RF and negative ACPA (0) 
- Low positive RF or low positive ACPA (2) 
- High positive RF or high positive ACPA (3) 
3. Acute-phase reactants (0-1) 
- Normal CRP and normal ESR (0) 
- Increased CRP or ESR (1) 
4. Duration of symptoms (0-1) 
- Less than 6 weeks (0) 
- 6 weeks or more (1) 
Target population: Patients who have at least one swollen joint that is not better explained by 
another disease. Points are shown in parentheses. Cutpoint for definite rheumatoid arthritis is 6 
points or more. Patients can also be classified as having rheumatoid arthritis if they have: (a) 
typical erosions; (b) long-standing disease previously satisfying the classification criteria.  
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1.1.5.2 DISEASE ACTIVITY SCORES 
To assess disease activity in RA several combined indices have been 
developed and below I describe some of these: Disease activity score 28-ESR 
(DAS28-ESR) is one of the most widely used both in clinical practice and in 
studies (Table 3). A similar score is the DAS28-CRP, where ESR has been 
exchanged for CRP. Another widely used index is the Clinical disease 
activity index (CDAI), which is a simpler variant than the DAS28 scores. 
With these instruments the rheumatologist can assess whether the patient is in 
remission or has low, moderate or high disease activity (Table 3).  
 Composite measures of disease activity Table 3.
Indices Components Cutpoints for disease activity 
  Remission Low  Moderate  High  
DAS28-ESR TJC28, SJC28 ESR, PGA ≤2.6 >2.6 to ≤3.2 >3.2 to ≤5.1 >5.1 
DAS28-CRP TJC28, SJC28 CRP, PGA ≤2.6 >2.6 to ≤3.2 >3.2 to ≤5.1 >5.1 
CDAI TJC28, SJC28 PGA, EGA ≤2.8 >2.8 to ≤10 >10 to ≤22 >22 
      
CDAI, Clinical disease activity index; DAS28, Disease activity score 28; EGA, Evaluator 
global assessment, ESR, erythrocyte sedimentation rate; PGA, Patient global assessment; 
SJC28, Swollen joint count 28; TJC28, Tender joint count 28. 
 
1.1.6 PROGNOSIS AND TREATMENT 
Factors predicting poor prognosis at disease onset are the presence of 
autoantibodies (RF and ACPA) 30, 47, 48, erosive joint changes on radiographs 
of hands and feet, high levels of inflammation measured (ESR, CRP) and 
multiple swollen joints. Studies have shown that patients treated early (<12 
weeks) from debut are more likely to achieve remission than those that are 
treated later 49. If improvement in disease activity is small after 3 months of 
treatment, the therapy is adapted and re-evalued 3 months later 26.  
For a large part of the 20th century there were no effective treatments for RA. 
This was apparent when Dr. Walter Bauer, the president of the American 
Rheumatism Association (ARA), addressed the ARA meeting in 1947 with 
the paraphrased words of Wendell Holmes: " If most of the so-called specific 
rheumatic medicines were thrown into the Atlantic ocean, it would be much 
better for mankind and so much worse for the fishes" 50. Nonsteroidal anti-
B cell subpopulations in the pathogenesis of RA 
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inflammatory drugs (NSAIDs) were then used for pain and stiffness as they 
are now. However they do not change the course of disease. There was a 
major breakthrough in 1948 with the discovery of corticosteroids, which gave 
patients a miraculous symptomatic improvement and disease-modifying 
effects 51, 52. This discovery earned Kendall, Hench and Reichstein the Nobel 
Prize in 1950 53. However, it soon became apparent that the patients got 
serious side effects if they were treated with corticosteroids permanently and 
that other treatments were needed 54. There are now many disease-modifying 
antirheumatic drugs (DMARDs) in use for RA and they are divided into 
main two classes: synthetic and biologic DMARDs (bDMARDs). Synthetics 
are further divided into conventional (csDMARDs) and targeted 
(tsDMARDs) 26. Use of csDMARDs has evolved empirically and their modes 
of action are still largely unknown e.g. methotrexate, which is the most 
commonly used csDMARD. The second major breakthrough in the treatment 
of RA came late in the 90's with the first bDMARD, the tumor necrosis factor 
(TNF) inhibitors that revolutionized the treatment of RA 55. We now have 
other bDMARDs that target other cytokines (e.g. IL-6 and IL-1) and cells (B 
cells and T cells). The tsDMARDs, which are a relatively new drug category, 
include Janus kinase (JAK) inhibitors that seem to have a good effect in RA 
26.  
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1.2 B CELLS 
B (bursal or bone marrow-derived) cells are an essential part of the adaptive 
immune system and humoral immunity and are thought to have evolved in 
jawed vertebrates more than 500 million years ago 56. As terminally 
differentiated plasma cells they are known for their ability to secrete 
antibodies. However, they can also be efficient antigen presenting cells and 
secrete cytokines 56.  
Figure 2. Human B cell development and differentiation. B cells arise from the 
common primary lymphoid progenitor (CLP) cells in the primary lymphoid 
organs (PLO) i.e. fetal liver and fetal/adult bone marrow. There they develop 
through pro-B and pre-B cell stages into immature cells 57. They emerge from the 
PLO, as transitional cells and migrate to the spleen where they further 
differentiate into naive cells 58. Naive cells circulate through blood and secondary 
lymphoid organs (SLO). Within SLO such as lymph nodes or spleen, naive B cells 
are activated and differentiate into memory B cells (MBCs) or plasmablasts that 
further differentiate into plasma cells. MBCs can migrate and reside in peripheral 
tissue. Plasma cells have a preference for bone marrow and GALT (gut 
associated lymphoid tissue) 58, 59. GC, germinal center. 
In mice, B cells can be divided into two populations: B1 and B2 cells, of 
which the former can be divided into B1a and B1b and the latter into 
follicular (FO) and marginal zone (MZ) B cells according to ontogeny and 
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anatomic distribution 60-62. However this classification is debated in humans. 
B1 cells in mice develop mainly in the fetal liver and are thought to play a 
role in innate immunity. They go to pleural and peritoneal cavities as well as 
spleen and secrete natural antibodies that are the first line of immune defense 
in blood 57, 60. In humans a CD5+ B1-like population is found but it is unclear 
whether it is a human counterpart to the B1 population in mice 62. Human B2 
cells, also called follicular B cells, develop near the end of fetal life (in fetal 
liver) and all through adult life (in bone marrow) (Figure 2). MZ B cells in 
mice derive their name from their location in the marginal zone in the spleen 
60. Whether a true MZ B cell population exists in humans is debated. 
However, human IgM+ IgDlow memory B cells (MBCs) are in many ways 
similar to the MZ B cells in mice and it has been proposed that they are the 
MZ B cell counterpart in humans 61.  
1.2.1 B CELL RECEPTOR AND CO-RECEPTOR 
COMPLEX 
1.2.1.1 THE B CELL RECEPTOR  
B cells express a membrane-bound antibody that recognizes specific 
antigens. The antibody i.e. immunoglobulin (Ig), combined with α-and β-
chains, which transmit signals to the cells core, comprise a B cell receptor 
(BCR) (Figure 3A) 56. Antibodies exist in two forms; either expressed on the 
surface of B cells or secreted as soluble factors. They are composed of two 
identical heavy and light chains (Figure 3B).  
Figure 3. A. The BCR and the B cell co-receptor complex. B. Figure depicts 
antibody structure composed of light chains (green) and heavy chains (pink). 
Each light and heavy chain has a constant domain (grey) and a variable domain 
(purple). Fab region and Fc region are indicated with lines.  
Figure adapted from Thorarinsdottir et al. SJI 63.  
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The Fab portion of the antibody recognizes the antigen. The Fc region is 
important for the function of the antibody and can be of different isotypes or 
classes i.e. IgM, IgD, IgA, IgE or IgG. The variable domain has three regions 
that come in contact with the antigen, called the complementarity-
determining regions (CDR1 to CDR3) with the CDR3 having the greatest 
diversity of the CDR regions.  
1.2.1.2 THE B CELL CO-RECEPTOR COMPLEX 
The BCR co-receptor, composed of CD19, CD81 and the complement 
receptor 2 (CR2, CD21), lowers the threshold of BCR activation. It is thought 
to occur via a co-ligation of the BCR and its co-receptor, which results in the 
phosphorylation of the CD19 tail by a BCR-associated tyrosine kinase and an 
amplification of the BCR signal to the cells core. It has been proposed to 
occur when the BCR and the BCR co-receptor bind simultaneously to an 
opsonized antigen with the BCR binding to the antigen and CD21 to a 
complement fragment on the surface of the antigen, respectively (Figure 4). 
 
Figure 4. BCR and BCR co-
receptor bind to an antigen 
and a complement fragment, 
respectively, leading to the 
activation of the B cell. Figure 
from Thorarinsdottir et al. SJI 
63 
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In addition to binding to complement fragments (C3d, C3dg and iC3b), 
CD21 has been proposed to bind the Epstein-Barr virus 64, the Fc-receptor for 
IgE (FcεRII or CD23) 65, prions 66 and interferon-α 67. CD21 can be found on 
the surface of B cells, follicular dendritic cells, thymocytes and a subset of T 
cells. B cells go from expressing low levels to high levels of CD21 when they 
develop from transitional to naive cells 68. They lose a substantial amount or 
all CD21 molecules when they differentiate further into plasmablasts and 
plasma cells 69. In addition, the B cells continuously shed CD21 and this 
shedding is thought to increase upon activation of the B cells 70, 71. Soluble 
CD21 can form biologically active complexes with CD23 and complement 
fragments but the function of these are outside the scope of this thesis 72, 73.  
1.2.1.3 TOLL-LIKE RECEPTORS 
B cells express pattern-recognition receptors (PRRs) including Toll-like 
receptors (TLRs) that bind conserved pathogen components (pathogen-
associated molecular patterns, PAMPs) but can also bind self-antigens 74. The 
TLRs recognizing bacteria and fungi are expressed on the cell surface and 
TLRs binding viral or microbial nucleic acids e.g. TLR7 and TLR9, are 
found on intracellular membranes 75.  
1.2.2 B CELL DEVELOPMENT IN BONE MARROW 
There are checkpoints during the B cell development in the bone marrow to 
ascertain that the B cells develop into harmless functioning cells i.e. that they 
have a diverse antibody repertoire, and do not recognize self-antigens 76. This 
selection process entails testing the function of the BCR and its precursor, the 
pre-BCR. The common lymphoid progenitors (CLPs) give rise to progenitor 
(pro)-B cells that further develop into precursor (pre)-B cells77. At this stage 
the pre-B cell receptor composed of the µ heavy chain and the surrogate light 
chain (SLC) is tested. This checkpoint tests whether the heavy chain is 
functional and whether it can pair with the invariant SLC. Development of 
human B cells stop at this stage if the pre-BCR fails this test. However, the 
loss of the SLC in B cells in mouse only leads to a partial block 78. 
Subsequently, the pre-B cells develop into a BCR-expressing immature cell 
where the next checkpoint tests whether the BCR is autoreactive. If the 
combination of light chains and heavy chains result in an autoreactive BCR 
the light chain undergoes new light chain rearrangements 79. If the B cells 
continue to express high-affinity autoreactive BCRs the cells go into 
apoptosis (clonal deletion) or become unresponsive (clonal anergy) 57, 77. 
Those that are not negatively selected migrate from the bone marrow as 
transitional cells. Only around 15% of the generated B cells in the bone 
marrow reach peripheral blood. The selection process in the bone marrow is 
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called central tolerance. In the periphery further selection takes place and is 
called peripheral tolerance 80. 
1.2.3 TRANSITIONAL AND NAIVE B CELLS 
1.2.3.1 TRANSITIONAL CELLS 
The next tolerance checkpoint is at the transitional B cell stage and is also 
testing the BCR's ability to bind to self-antigens. BCR signaling is necessary 
for survival but too strong a signal at this stage leads to apoptosis and in 
humans a reduction from 40% to 20% in autoreactive cells is seen 80, 81. The 
transitional cells comprise around 5% of the total B cell population in 
peripheral blood 82 whereas the proportions are much higher in cord blood 83. 
These newly migrated cells travel to the spleen. Transitional B cells can be 
divided into three populations in an order of development: T1, T2, T3 84.  
1.2.4 NAIVE B CELLS AND FORMATION OF 
MEMORY AND ANTIBODY-SECRETING CELLS 
The majority of the peripheral blood B cells are composed of naive cells that 
circulate through blood and SLO, with a lifespan of a few weeks 58. They 
have decreased their surface expression of IgM and upregulated IgD 
compared to transitional cells 58 . 
Immunological memory is the function of memory cells and antibody-
secreting cells 85. The primary response to an antigen forms the 
immunological memory, which upon re-encounter with the antigen will 
respond faster and in an amplified affinity-matured manner (secondary 
response). This usually means that the secreted antibodies are switched from 
IgM to IgG and/or IgA 85.  The B cell memory responses can be formed in a 
T-cell dependent (TD) or T-cell independent (TI) manner, which will now be 
shortly described, beginning with the TD response where the antigen is a 
protein. The naive B cell in the SLO binds its cognate protein antigen via the 
BCR and internalizes the antigen-BCR complex. After processing the protein 
the B cell presents the peptides via MHC class II molecule to an activated 
helper T cell at the border of the T-cell zone and the B cell follicle. The B 
cell receives co-stimulatory signals from the T cell i.e. CD40 ligand and 
cytokines 58, 85. The activated B cell now either becomes an extra-follicular 
short-lived plasma cells, or forms a histological structure called the germinal 
center (GC) in the B cell follicle. The short lived plasma cell secretes mainly 
IgM but can later secrete isotype-switched antibodies 85. However, in the GCs 
the B cells usually go through class-switch from IgM to IgG, IgA or IgE. In 
addition, the B cells clonally expand and their BCRs accumulate somatic 
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hypermutations (SHM) in their variable domain resulting in high-affinity 
BCRs. Both long-lived MBCs and long-lived plasma cells arise from the GCs 
59, 68, 85.  
The TI antigens are not proteins and they contain multiple epitopes, which 
can crosslink numerous BCRs. TI antigens can be divided into TI-1 and TI-2 
antigens. TI-1 antigen, e.g. lipopolysaccharides (LPS), is a polyclonal 
activator as it also activates TLRs via TLR ligands, whereas TI-2 antigen e.g. 
polysaccharides, needs additional signals to activate the B cells 84, 86, 87. The 
response to TI antigens usually does not generate MBCs but instead plasma 
cells that secrete low-affinity antibodies 58.  
1.2.4.1 MEMORY B CELLS 
The widest definition of a MBC is a cell that has been activated by an antigen 
inducing a response and that remains responsive to a second encounter with 
the same antigen. The MBCs as a group have typical and important 
characteristics such as: Class-switching, SHM, clonal expansion and a 
lifespan of decades. In addition they can proliferate and/or differentiate more 
efficient and faster than naive B cells upon stimulation 58, 84. When looking at 
specific types of MBC they often do not possess all of those characteristics, 
e.g. there are IgM+ MBCs that have none or few SHM 58.  
In humans, the TNF superfamily member CD27 has become a universal 
marker of MBCs 88 but there are exceptions to this as not all MBCs express 
CD27. In peripheral blood the main types of MBCs are IgG+ and IgA+ CD27+ 
MBCs. However, the majority of IgA+ MBCs is localized in the mucosa-
associated lymphoid tissue (MALT). The IgG+ MBCs in humans are further 
divided into IgG1, IgG2, IgG3 and IgG4 (in a descending order of 
frequency). Although class-switched MBCs are thought of as typical MBCs, 
the IgM+-only (i.e. IgM+IgDlow/-) and IgM+IgD+CD27+ MBCs constitute 
around 5% and 15% of the peripheral blood B cells respectively. IgD and IgE 
MBCs are hardly detectable in peripheral blood 58. Approximately 20-25% of 
the IgG+ MBCs 89 and some of the IgA+ MBCs lack CD27 90. A large 
proportion of these cells seem to be GC derived and they are often derived 
from a common GC clone 58.  
Antibody-secreting cells can be divided into plasmablasts and plasma cells 
where plasmablasts often are thought of as an intermediate stage to plasma 
cells 91. Plasma cells can be either short-lived, found at extra-follicular sites, 
or long lived, residing in the bone marrow or gut-associated lymphoid tissue 
(GALT). In humans long-lived plasma cells have been found to live around 
20 years but more studies are needed 59. In contrast to MBCs the plasma cells 
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are terminally differentiated, do not proliferate and have usually 
downregulated their BCR 59. 
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1.3 CD21-/LOW B CELLS 
In the following chapters the B cell populations and studies referred to are in 
humans, unless otherwise stated. The expression of CD21 varies on different 
B cell populations (Table 4). There is low expression on early transitional 
cells (T1) whereas naive cells and MBCs express CD21. However, 
plasmablasts and plasma cells lack or have low levels of CD21. Activation of 
a B cell can lead to lower expression levels 72. In addition, different groups of 
researchers have reported an increase of CD21-/low B cell populations in 
various diseases albeit using different definitions of these populations in 
terms of markers. Nevertheless, these CD21-/low B cell populations share 
many similarities, as described below.  
 Cell surface markers on different B-cell populations Table 4.
T1, T2, T3 are transitional cells. MBCs, memory B cells. 
1.3.1 CD21-/LOW B CELLS IN MOUSE MODELS 
Different CD21-/low B cell populations have been identified in mouse models. 
One of these was described in the surrogate light chain knockout (SLC-/-) 
mouse model.  This is a knockout mouse model where the genes of the SLC 
have been deleted leading to an absence of SLC on pre-B cells. In mice that 
lack the transmembrane region of the antibody µ heavy chain, B cell 
development is arrested at the pro-B cell stage in the bone marrow being 
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T1 -/low + +++ + - +++ +++ - +++ + - 
T2 + + +++ low - ++ ++ - ++ ++ - 
T3 + + + -/+ - + + - + ++ - 
Naïve + + + - - + + - + ++ - 
IgM IgD-/low 
MBCs + + + - + ++ -/+ - +++ +/- - 
CD27+IgD-
MBCs + + + - + ++ -/+ - - - + 
Plasmablast -/low low - - +++ - +++ + - - - 
Plasma cell92 - - /+  - - +++ - +++ +++ - - - 
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unable to develop into pre-B cells. The absence of SLC should also halt the 
development of B cells at the same stage, as SLC is used to test whether the 
heavy chain is functional. However, mice that lack one or all of the SLC 
components (VpreB1, VpreB2, λ5) do not show a complete block but rather 
an impairment at this stage, allowing some B cells to still develop 93. Keenan 
et al. found that pre-B cells could even develop in the combined absence of 
SLC and bona fide light chains 94. Nevertheless, despite lower B cell 
numbers, in the spleen the SLC-/- mice had an increased proportion of MZ B 
cells and an increase of a B cell population that lacked the markers 
characterizing FO, MZ and B1 cells, CD23, CD21 and CD43 respectively. 
This subset was therefore termed CD21-CD23- (hereafter called CD21-/low 
cells) 94. Later work showed that in adult control mice, most of the CD21-/low 
cells were naive B cells but in the SLC-/- mice they were MBCs expressing 
mainly IgM 95. The SLC-/- mice had an increase in IgM and IgG 
autoantibodies, predominantly IgG2b and IgG3. However, only the CD21-/low 
cells from SLC-/- mice and not control mice produced IgG autoantibodies 
upon stimulation with LPS. The MZ B cells were responsible for the IgM 
autoantibodies 96. 
The frequency of CD21-/low cells increase with age in both the SLC-/- and 
control mice and their phenotype is similar to another CD21-/low B cell 
population that in 2011 was described simultaneously by Marrack and 
Cancro 97, 98. This B cell population also accumulated with age, hence the 
name Age-associated B cells (ABCs). Their frequency varies between 
individual mice but for unknown reasons emerge sooner and with higher 
numbers in female mice 97-99. The ABCs are found in peripheral blood, spleen 
and bone marrow but rarely in lymph nodes 99. The two groups defined the 
ABCs differently. Marrack et al. used CD11c and CD11b as markers in 
combination with B220 whereas Cancro et al. relied on another combination 
of markers including CD19, CD43, CD93, CD21 and CD23 in order to 
distinguish the ABCs from immature, B1, MZ and FO B cells 97, 98. The 
CD11c+CD11b+ABCs were competent antigen presenting cells and localized 
to the B/T cell border 97, 100. Most ABCs were mature and unswitched and 
upon stimuli they differentiated into plasma cells and were prone to switch to 
IgG2a/c 97, 98, 101.  
1.3.2 CD21-/LOW B CELLS IN HEALTH 
We have characterized the CD21-/low B cell population in healthy donors 
(HDs) that will be further presented in Results, study I. Otherwise there are 
few studies performed on CD21-/low B cells in HDs. In 2005 a new MBC 
population was described in the tonsils of HDs. It constituted around 10% of 
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the B cell population in the tonsils and lacked the CD27 memory marker as 
well as CD21 and CD38 and was defined by its expression of the low affinity 
receptor for IgA i.e. Fc-receptor-like protein 4 (FcRL4) 102. The FcRL4 was 
first thought be an inhibitory receptor but it seems be a modulator of response 
in that it can sensitize B cells to TLR9 stimuli culminating in NFκB 
activation 103. In addition, it has been shown in a group of HDs (0-50 years) 
that the frequency of a CD21-/low population, defined as CD21-
/lowCD38lowcells, increases slightly with age 82.  
1.3.3 CD21-/LOW B CELLS IN DISEASE 
1.3.3.1 INFECTIONS 
CD21-/low B cells are increased in various chronic infections and have been 
described in virus infections such as Human immunodeficiency virus (HIV) 
104, 105, Hepatitis C virus (HCV) 106, 107 and Hepatitis B virus (HBV) 108 
infections as well as in tuberculosis (Mycobacterium tuberculosis) 109 and 
malaria (plasmodium species) 110.  
Whether the CD21-/low B cell expresses CD27 differs between the diseases 
investigated. In HCV, tuberculosis and malaria a CD21-/low population 
lacking CD27 accumulate in infected individuals 104. However, there is a 
clonal expansion of CD21-/lowCD27+ cells in HCV patients with mixed 
cryoglobulinemia, a lymphoproliferative disorder with autoantibody 
production e.g. RF and autoimmune manifestations 111. 
A CD21-/low B cell population that is CD27- and CD11c+ can comprise over 
15% of all B cells in the people living in malaria endemic areas 112. The 
expression of CD11c is also found in CD21-/low B cell populations in HIV 104 
and HCV 113. Additionally, the CD21-/low populations in HIV, HCV and 
tuberculosis express FcRL4 114, which could be due to TLR stimulation 115 or 
the pathogen itself 116. In HCV, the proportion of CD21-/low B cells that 
express FcRL4 correlates positively with liver inflammation 117. In contrast, 
the CD21-/low cells in malaria do not express FcRL4 but rather seem to 
express FcRL5 110.  
In these chronic infections the CD21-/low B cells have been called "exhausted" 
because in HIV, HCV and malaria they have a decreased proliferation and/or 
differentiation capacity after BCR stimulation. Nevertheless, the response 
varies between these diseases with the population in malaria being least 
responsive i.e. proliferating less than naive cells upon combined stimuli (anti-
Ig, anti-CD40, IL-10 and IL-4 and TLR9-agonist) and not differentiating into 
plasma cells when stimulated with TLR9-agonist, Staphylococcus aureus 
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Cowan 1 (SAC), pokeweed mitogen and IL-10 110. In contrast, in HCV mixed 
cryoglobulinemia the cells proliferated upon combined stimuli (anti-Ig, 
CD40L, TLR9-agonist, IL-2 and IL-10) 111 and in HIV although they had 
diminished proliferative response when stimulated with anti-Ig, CD40L, IL-2 
and-10, they could secrete antibodies upon polyclonal activation (SAC and 
TLR9 agonist) 104.  
There is evidence pointing to the pathogen as the driving force behind the 
expansion of the CD21-/low population in these infections. Firstly, the 
frequency of CD21-/low B cells in HIV correlates to a certain extent with the 
viral load 105, 118. Secondly, there is an enrichment of pathogen-specific B 
cells in the CD21-/low populations in HIV 104 and malaria 112, 119. Thirdly, the 
frequency of CD21-/low cells decreases or disappears with successful 
treatment against tuberculosis and antiviral therapy in HIV and HCV 114. 
Finally, the expansion of CD21-/low cells was only found in malaria-exposed 
individuals compared to age-matched controls in similar villages not exposed 
to malaria 120. 
Taken together, the CD21-/low cells in aforementioned chronic infections 
usually have attenuated response to stimuli, often have upregulated 
characteristic cell surface markers i.e. CD11c and FcRL4 and in some of 
these infections the underlying pathogen seems to drive their expansion.   
1.3.3.2 CD21-/LOW B CELLS IN IMMUNODEFICIENCIES 
Common variable immunodeficiency (CVID), characterized by an absence of 
the switched antibodies IgG and IgA with/or without lack of IgM is the most 
common primary immunodeficiency in adults 121. An expansion of CD21-/low 
B cells to more than 20% of all peripheral blood B cells defines a group Ia of 
CVID patients that are prone to get autoimmune cytopenia and splenomegaly 
121. Isnardi et al. showed that the CD21-/low cells in this patient group 
expressed FcRL4 and lacked CD27. In addition, they were shown to be IgM+, 
enriched for autoreactivity and to exhibit reduced proliferation after stimuli 
with BCR and CD40L without losing the ability to secrete antibodies 122.  
An increase of CD21-/low B cells, defined as CD21-/low CD38-/low, has also 
been described in other immunodeficiencies e.g. Wiscott-Aldrich syndrome 
123 and CTLA-4 haploinsufficiency-associated immune dysregulation 124. 
1.3.3.3 CD21-/LOW B CELLS IN AUTOIMMUNITY 
Chronic infections and autoimmune diseases share their chronic state of 
inflammation where the immune system is not able to rid the body of the 
antigen. Also similar to that in chronic infections, an increase of CD21-/low B 
B cell subpopulations in the pathogenesis of RA 
 26 
cells in peripheral blood has been described in autoimmune diseases e.g. 
systemic lupus erythematosus (SLE) 121, primary Sjögren's syndrome 125, 
multiple sclerosis 126 and IgG4-related disease 127. One of the earliest studies 
of CD21-/low B cells in autoimmune diseases was on RA patients. It will be 
described later in chapter 1.4 B cells in RA. 
In SLE there is an increase of a CD21-/low B cell population (CD38-) during 
acute flares 128 and a similar population has been correlated to disease 
duration 129. A CD21-/low B population (defined as CD27-) has been identified 
in primary Sjögren's syndrome that expresses CD11c and correlates with 
lymphoproliferation 125. In some of these autoimmune diseases the CD21-/low 
B cell population has been associated with autoreactivity, e.g. it was enriched 
in autoreactive clones in both SLE 128 and primary Sjögren's syndrome 125. 
Comparable to the CD21-/low B cell population in chronic infections, it has a 
diminished proliferative capacity in primary Sjögren's syndrome as the 
CD21-/low did not respond to BCR stimulation only but proliferated upon 
stimulation with anti-Ig, CD40L and TLR9 agonist 125. 
In summary, the CD21-/low B cells in autoimmune diseases have similar 
properties to the CD21-/low B cells found in chronic infections, i.e. they often 
express CD11c and exhibit attenuated response to stimuli. Additionally, in 
some of these autoimmune diseases the CD21-/low B cells are enriched with 
autoreactive clones. This indicates that the underlying disease (i.e. 
autoantigen) drives the expansion of CD21-/low B cells, which is again 
reminiscent of the pathogen driving the expansion of CD21-/low B cells in 
chronic infections.  
1.3.3.4 CD21-/LOW B CELLS AFTER CHECK POINT INHIBITORS 
Check point inhibitors are a new treatment strategy in cancer where the 
"breaks" are lifted of the immune system leading to an immune attack on the 
cancer cells. The "breaks" that are lifted, i.e. inhibited, are Programmed cell 
death protein 1 (PD-1) and Cytotoxic T-lymphocyte antigen-4 (CTLA-4). 
Interestingly, this has also resulted in autoimmune side effects, e.g. rashes, 
arthritis and inflammatory bowel disease. Analysis of the B cell compartment 
after treatment of melanoma patients with check point inhibitors revealed that 
a combination therapy with anti-PD-1 and anti-CTLA-4 or only anti-CTLA-4 
resulted in a decrease in total B cells and an increase in a CD21-/low B cell 
population as well as plasmablasts. These CD21-/low B cells were PD-1+ and 
proliferating (Ki-67+). The changes in B cell count and composition 
coincided with the development of immune-related adverse events mainly 
affecting skin, colon and liver 130. This suggests a possible role of the CD21-
/low B cells in the autoimmune symptoms.  
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1.4 B CELLS IN RA 
1.4.1 B CELLS IN PERIPHERAL BLOOD 
1.4.1.1 PATIENTS WITH EARLY RA  
There are a few studies that have analyzed the B cell compartment in 
peripheral blood of early RA patients, whereas there are studies on B cells in 
patients with established RA (see below 1.4.1.2). In studies on early RA the 
disease duration is usually less than 12 months. Figure 5 summarizes the 
main findings in studies on B cell populations in early and established RA.  
Figure 5. The main B cell populations in peripheral blood investigated in RA 
studies. Box describes results from studies comparing B cell populations in early 
RA (left) and in established RA (right) compared to HDs.* Study was on untreated 
RA patients but disease duration was 2-26 months. MBC, memory B cell. 
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Most of the studies on early RA show a decrease in the proportion and/or 
absolute count of the CD27+ unswitched MBCs compared to HDs 131-133. 
Some also detect a decrease in the frequency of total CD27+ MBCs in these 
patients compared to HDs 131, 133. This decrease is evident already a year prior 
to disease onset 134. McComish et al. also looked at the CD21-/low B cells, 
defined as CD21-/lowCD38-, in untreated RA patients and compared to HDs, 
observed a slight increase in the frequency of these cells, a frequency similar 
to that in treated patients with established disease 133. In addition, one study 
has reported an increase in the frequency of CD27-IgD- (double negative, 
DN) MBCs B cells in untreated early RA patients compared to HDs 135.  
1.4.1.2 PATIENTS WITH ESTABLISHED RA 
1.4.1.2.1 B cell populations 
Studies have reported lymphopenia 136, 137 and/or B cell lymphopenia in 
established RA 137-142. This does not seem to be specific for RA as it has also 
been found in other autoimmune joint diseases e.g. psoriatic arthritis 140. 
There could be an association between B cell lymphopenia and disease 
duration as one study found a positive correlation between those two 
parameters 138.  
Studies have reported a decrease in the proportion of CD27+ unswitched 
MBCs in patients with established RA compared to HDs (Figure 5) 143-145. 
However, there are contrasting reports regarding the proportion of CD27+ 
switched MBCs 137-139, 143, 144, 146. In addition, a number of publications have 
found an increase in DN MBCs in established RA patients compared to HDs 
135, 136, 145. One study reported an increase in DN MBCs and plasmablasts in 
patients with established compared to early RA 147. 
An increase in activated (CD86+) cells in both the naive and CD27+ MBC 
subset in the blood of patients with RA compared to HDs has been described 
148. In line with this Adlowitz et al. reported an increase in activated cells, 
defined as CD21-/low cells in the switched and DN MBC populations 149. 
Another CD21-/low population described as increased in older female RA 
patients is the CD11c+ CD21-/low population that also correlated with age in 
the female RA patients 97. McComish et al. also found an increase in CD21-
/low CD38- cells in patients with established RA as they had found in untreated 
RA patients 133. However, one of the most detailed studies on CD21-/low B 
cells in RA is the study by Isnardi et al. from 2010 150. In this paper they 
described an increase in an autoreactive CD21-/low B cell population in blood 
of RA patients compared to HDs. The researchers first investigated the 
CD21-/low B cell population in CVID patients where the patients had severely 
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decreased frequencies of MBCs. Because of this they defined the CD21-/low B 
cell population as CD19+CD27-CD21-/low in the CVID patients and went on to 
study the same B cell population in RA patients. They found the CD27-CD21-
/low to be increased in both CVID and RA patients compared to HDs. Around 
30% of the CD27-CD21-/low were IgMlowIgD+ and 20% were switched. 
Because the Igs from this CD21-/low B cell population were devoid of SHM 
they deduced that the cells were naive. The IgMs from the CD21-/low cells 
displayed an increased frequency of autoreactive clones compared to CD27-
CD21+ cells in both HDs and RA patients. In the RA patients a large fraction 
of the CD21-/low clones were highly HEp-2 reactive 150. As in above-
mentioned autoimmune diseases CD27-CD21-/low cells from patients with RA 
did not respond well to BCR and CD40 costimulation. However, they did 
upregulate the activation markers CD25 and CD69 after TLR9 triggering. 
Gene expression analysis (microarrays) of the CD21-/low cells showed an 
upregulation of genes for inhibitory receptors as well as of CD11c 150.  
1.4.1.2.2 Effect of treatment on B cell populations 
It is difficult to know when looking at the B cell populations in established 
RA whether the changes seen in B cell populations compared to HDs, are due 
to the disease itself or other factors e.g. treatment with DMARDs. The most 
commonly used treatment is with the csDMARD methotrexate, where a trend 
of normalization of both the frequency and absolute number of B cells was 
observed four months into therapy 131, and steroid dose was positively 
correlated with the proportion of MBCs, especially switched MBCs 138. 
Studies that have looked at the effect of bDMARDs and tsDMARDs are 
described below and summarized in Table 5. 
An increase in the frequency and/or absolute number of the total B cell 
population has been reported after treatment with TNF- 138, 140, IL-6 receptor 
inhibitors 139 and JAK inhibitors 142. With the JAK inhibitors this increase 
was seen relatively early, at 8-12 weeks but with a progressive reduction at 
later time points 142. 
TNF inhibitors have been found to increase unswitched MBCs 143, 145 and 
switched MBCs (only detected in seronegative patients) 142 and decrease in 
activated CD86+ cells 148 and proportions of DN MBCs 135. An inverse 
association between the number of previous TNF inhibitors used and 
proportions of DN MBCs has also been described 138. A high proportion of 
CD27+ MBCs before treatment start with TNF inhibitors has been associated 
with good clinical response 138.  
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 Effect of bDMARDs and tsDMARDs on total and MBC Table 5.
populations 
B cell populations TNF inhibitors 
IL-6 receptor 
inhibitors  
JAK 
inhibitors  CTLA4-Ig 
Anti-CD20 
antibody 
Total B cells Increase Increase Increase Not known Decrease 
Unswitched MBCs Increase Decrease Not known Decrease Decrease 
Switched MBCs 
Increase 
(seroneg 
only) 
Decrease Not known Decrease 
Decrease 
DN MBCs Decrease Decrease Not known Not known Decrease 
 
Studies on IL-6 receptor inhibitors have reported an effect on the DN MBCs 
(Table 5). IL-6 receptor inhibitors seem to decrease the frequency of total DN 
MBCs 135, 145 or a DN subset, i.e. IgA+ DN MBCs 136. A lower frequency of 
DN MBCs at baseline was associated with good clinical response to IL-6 
receptor inhibitors 136. One study reported a decrease in the proportion of 
switched and unswitched MBCs (DN proportions were not reported) 139.  
A T cell inhibitor, CTLA-4 inhibitor (abatacept) seems to decrease the 
proportion of switched 141, 144 and unswitched MBCs (Table 5) 141.  
Rituximab, a B cell depleting therapy, is an anti-CD20 monoclonal antibody. 
After rituximab treatment the reconstitution of B cells in blood occurs first 
with T1/T2 then T3 transitional cells and finally the naive. One of the first 
studies on the effect of rituximab on B cells in RA patients showed that 
patients with incomplete B cell depletion after one cycle of rituxmab had 
poorer outcome 151. The B cells remaining in the blood after rituximab 
therapy i.e. those resistant to depletion, are mainly CD21-/low DN MBCs and 
large proportion of the DN MBCs was also CD95+ 149.  Baseline 
characteristics that can indicate good response to treatment have been found 
to be a lower frequency of CD27+ MBCs 137, an increased DN MBCs 152 and 
a lower proportion of CD95+ cells in DN and switched MBCs 149.  
Regarding relapse after rituximab treatment, a study reported that responders 
that relapsed early (week 24-40 after treatment) had a higher proportion of 
CD27+ MBCs before starting rituximab treatment than responders with late 
relapse (week 48-133 after treatment) 153. It has also been shown that patients 
relapsing at the time of B cell repopulation tended to show a higher frequency 
of MBCs at repopulation as compared with patients who relapsed later 154. 
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1.4.1.2.3 B cell populations and clinical parameters 
Considering autoantibodies, one study found that titers of ACPA correlate 
positively with absolute numbers of plasmablasts and negatively with 
absolute numbers of switched and unswitched CD27+ MBCs in peripheral 
blood 133. An inverse correlation between RF titer and absolute numbers of 
IgM MBCs was also reported.133  
Disease activity score (DAS 28) has been found to correlate positively with 
the absolute numbers and proportions of plasmablasts 133, 145 and the 
proportion of CD86+ cells 132, and negatively with the absolute numbers of B 
cells 140 and circulating MBCs in peripheral blood 144. In fact, high frequency 
of both DN and unswitched MBCs 138 has been associated with higher disease 
activity. In addition, there was a positive correlation between the frequency 
of unswitched MBCs and DAS28 after three months of treatment with IL-6R 
inhibitors 139. 
Many studies do not find any effect of gender or age on B cell populations in 
peripheral blood in RA. Considering gender, there are conflicting results 
regarding this and proportions of MBCs 133, 138. However, there are some 
studies that have seen a decrease in the absolute numbers of plasmablasts, 
transitional B cells and MBCs 133 as well as in the proportion of unswitched 
MBCs with age 138.  In contrast, increased disease duration has been linked to 
an increase in CD27+ MBCs 146.  
1.4.2 B CELLS IN THE JOINTS 
The joints are the main target tissue in RA and previous work has shown that 
synovium and synovial fluid (SF) of RA joints are infiltrated by leukocytes 
such as granulocytes, monocytes, T and B cells 155. SF leukocytes are 
typically granulocytes. In contrast, the synovium rarely contains granulocytes 
but e.g. T cells are abundant. In the synovium the B and T cells often 
aggregate in follicles and sometimes they form ectopic GCs 156. It has been 
shown that some of these B cells are autoreactive that can recognize 
citrullinated proteins 36, 157.  
In RA patients the B cells in SF express lower levels or lack CD21 158, 159 but 
this does not seem to be disease specific as it is also seen in other non-RA 
arthritic diseases 159. The B cells in RA SF seem to be mainly MBCs and 
predominantly IgD-CD27+ or IgD-CD27- 160-162. In 2014, Yeo et al. found an 
enrichment of FcRL4+ cells in the SF and synovium of RA patients compared 
to blood (13% vs. 0.4%). These cells were CD21-/low and there was an 
enrichment of RANKL+ cells in the SF FcRL4+ cell subsets compared to 
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FcRL4- cells. The authors suggested that these cells could be pathogenic. The 
FcRL4+ cells were mainly switched (47%) or DN (41%) MBCs and they 
expressed higher levels of CD11c, CD80 and CD86 than FcRL4- cells. In 
addition, they produced TNFα suggesting a pro-inflammatory phenotype 160.  
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2 AIM 
The overall aim of this thesis was to identify B cell subpopulations that 
associated with pathogenicity in RA, i.e. whether there were any correlations 
between different B cell subpopulations and disease progression or 
autoantibodies.  
 
The specific research questions were addressed in three studies: 
• Study I: What is the phenotype and function of CD21-/low B cells 
in healthy donors? 
• Study II: Do CD21-/low B cells or other B cell populations 
associate with clinical parameters in patients with manifest RA?  
• Study III: Do CD21-/low B cells or other B cell populations 
associate with clinical factors or serum autoantibodies in the 
blood of patients with untreated early RA? 
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3 PATIENTS AND METHODS 
3.1 ETHICS 
All three studies were approved by the local ethical committee. All patients 
(Studies II-III) signed a written informed consent before entering the studies. 
Where no personal information or identity was recorded, as when collecting 
peripheral blood from HDs (Studies I-II) and tonsil samples (Study I), no 
written consent or approval by the Human Research Ethics Committee was 
needed (Swedish law 2003: 460, paragraphs 4 and 13). All mothers were 
given oral and written information for cord blood samples and gave oral 
consent to participate in the study (Study I).  
3.2 PATIENTS AND HEALTHY DONORS  
STUDY I: In this study we collected peripheral blood from 18 healthy 
women, aged 24–30 (n=9) and 55–64 years (n=9). Cord blood samples from 
six healthy newborn infants born at term (≥38 gestational weeks) and tonsils 
from six healthy children, aged 1–9 years undergoing tonsillectomy due to 
enlarged tonsils, were collected at the Sahlgrenska University Hospital. 
 STUDY II: For peripheral blood samples we recruited 24 patients with 
manifest RA from the outpatient clinic at Sahlgrenska University Hospital, 
Gothenburg and Uddevalla Hospital, Sweden. The inclusion criteria were: 
female; Caucasian, aged 30-70 years; diagnosis of RA according to ACR 
1987 criteria; disease duration 1-15 years. Exclusion criteria: Detectable 
autoimmune diseases other than RA; ongoing infection; cancer; previous or 
current treatment with B cell therapy. Disease activity was measured by 
swollen and tender joints, ESR, CRP and the composite index DAS28-ESR. 
In addition, ACPA and RF were measured. Disease severity was assessed 
according to radiographs of hands and feet. Eleven age- and sex-matched 
HDs were recruited. Patient and HD characteristics are shown in Table 6. 
For SF eight RA patients (6 females and 2 males) with swollen knee joints 
were recruited from the outpatient clinic at Sahlgrenska University Hospital. 
Patient characteristics are shown in Table 7. 
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 Clinical characteristics of patients and controls in Study II Table 6.
(peripheral blood analysis) 
Baseline characteristics 
ACPA+/RF+ 
patients 
(n=17) 
ACPA-/RF- 
patients 
(n=7) 
HDs 
(n=11) 
Age (years) 52±12 57±10 48±16 
Disease duration (years) 6±3 2 ±1 N/A 
Tender joint count (0-28) 0.7±1.2 3.9 ± 4.2 N/A 
Swollen joint count (0-28) 2.0±3.9 2.3±2.1 N/A 
Patient global assessment of 
disease activity (0-100 mm, 
VAS) 
29±23 33±25 N/A 
CRP (mg/l) 4±4 4±3 N/A 
ESR (mm/h) 9±7 13±9 N/A 
DAS28-ESR score 2.29±0.84 3.2±1.0 N/A 
Patient assessment of pain 
(0-100 mm, VAS) 25±18 30±18 N/A 
HAQ (0-3) 0.52±0.47 0.63±0.53 N/A 
Non-smoker   9 (53) 3 (43) N/A 
Current smoker  4 (24) 2 (29) N/A 
ACPA positive  15 (88) 0 N/A 
RF positive  10 (59) 0 N/A 
ANA positive  4 (24) 4 (58) N/A 
NSAIDs  10 (59) 5 (71) N/A 
Prednisolone 2 (12) 0 N/A 
csDMARDs    
     Methotrexate  16 (94) 5 (71) N/A 
     Sulfasalazine  4 (24) 2 (29) N/A 
     Hydroxychloroquine   1 (6) 0 N/A 
TNF inhibitors 7 (41) 1 (14) N/A 
  
Data are denoted as number of patients as well as proportions (%) for categorical data and 
means ± standard deviation for continuous data. ANA, anti-nuclear antibodies; HAQ, health 
assessment questionnaire; N/A, not applicable. 
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 Clinical characteristics of patients and controls in study II (used Table 7.
for SF and peripheral blood analysis 
ETN, Etanercept; ITP, idiopathic thrombocytic purpura; ND, not done; SZP, Salazopyrin 
  
Baseline 
characteristics 
 
Patients 
1 2 3 4 5 6 7 8 
Age (y) 26 21 61 34 53 30 51 62 
Gender F F M F M F F F 
Disease 
duration (y) 
6 16 37 3 21 2 10 16 
Smoker No No Yes No No No No Ex 
ACPA  pos neg pos neg pos pos pos pos 
RF pos neg pos neg pos pos pos pos 
ANA pos pos ND neg neg neg neg neg 
DMARDs  ETN SZP No  No ETN No  ETN No 
NSAID Daily No No As 
needed 
No  No As 
needed 
No 
Prednisolone 
(mg/d) 
5 /d No 5  5  No No No 7.5  
Other diseases No No ITP No No No No Psoriasis 
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STUDY III: Sixty patients with early untreated RA were recruited at the 
Rheumatology outpatient clinic at the Sahlgrenska University Hospital, 
Gothenburg, and the Rheumatology clinic at the University Hospital at 
Malmö and Lund. For comparison 28 age-and sex-matched donors were 
recruited. Inclusion criteria were: fulfilling the ACR/EULAR 2010 criteria 
for RA, ≥18 years old, at least 2 swollen joints and 2 tender joints, RF 
positive or ACPA positive or CRP ≥10 mg/ml, at least moderate disease 
activity (>3.2) by composite index disease activity score (DAS28)-CRP, 
duration of symptoms (retrospectively patient-reported joint pain) < 24 
months, and no treatment with DMARDs or prednisolon. Patient 
characteristics are shown in Table 8. 
 Clinical characteristics of patients and controls in study III  Table 8.
(peripheral blood analysis) 
Characteristics RA patients 
(n=60) 
HDs  
(n=28) 
Age, yr  55 ± 15 55±15 
Female, n (%) 44 (73) 17 (61) 
Symptom duration, mo  6 ± 4 NA 
Tender joint count, 0-28 10 ± 7 NA 
Swollen joint count, 0-28 9 ± 5 NA 
CRP,mg/l 25 ± 37 ND 
ESR,mm/h 34 ± 28 ND 
DAS28-CRP  5.07 ± 1.0 NA 
DAS28-ESR  5.5 ± 1.1 NA 
CDAI  30 ± 12 NA 
Patient global assessment VAS in mm 57 ± 21 NA 
HAQ-DI  1.04 ± 0.48 NA 
Non-smoker, n (%) 27 (45) ND 
Ex-current smoker, n (%) 43 (5) ND 
ACPA ≥ 20 IU/ml, n (%)  47 (78) ND 
RF ≥ 20 IU/ml, n (%) 46 (77) ND 
Data are denoted as number of patients as well as proportions (%) for 
categorical data and means ± standard deviation for continuous data. 
NA, not applicable; ND, not done. 
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3.3 METHODS 
3.3.1 RADIOGRAPHS OF HANDS AND FEET (STUDY 
II-III) 
Radiographs of hands and feet were performed in routine care after disease 
duration of 7.1 ± 5.1 years. A certified assessor blinded to clinical data 
evaluated the radiographs. Joint damage in hands and feet was quantified 
using the modified Sharp van der Heijde score (mSHS, 0-488), scoring for 
degree of joint erosion (16 areas per hand, 6 areas per foot) and joint space 
narrowing (15 areas per hand and 6 areas per foot). The median score for 
ACPA/RF positive patients was 20; to provide the categories of less damaged 
(Low mSHS) or more damaged joints (High mSHS) the patients were split by 
the median mSHS score into those < 20 and ≥ those 20 or above, 
respectively. 
3.3.2 FLOW CYTOMETRY AND FLOW CYTOMETRY 
BASED METHODS (STUDY I-III) 
The main methodology used in the present thesis is flow cytometry or 
fluorescence-activated cell sorting (FACS). Peripheral blood mononuclear 
cells (PBMCs) were isolated using Ficoll in Study I-II. Whole blood was 
used in Study III. Non-specific binding to Fc-receptors was inhibited with 
mouse, rat and rabbit serum. To delineate the different B cell subpopulations 
the following markers were used for flow cytometry: CD19, CD21, CD27, 
IgD, IgG, IgM, CD24, and CD38 (Study I-III); IgA, CD10 and CD243 
(ABCB1) (Study I). Additional cell markers were used to determine the role 
of the cells and activation status: CD40, CD62L, CD69, CD80, CD86, and 
CD95 (Study I) CD11c (Study I-II), and potential to mediate joint 
destruction: FcRL4, CXCR3, and RANKL (Study II).   
Gating strategy of the main B cell subpopulations is shown in Figure 6. First 
gating was done on PBMCs (Study I-II) or whole blood (Study III) with a 
lymphocyte gate. Then singlets were gated, and thereafter the CD19+ cells, 
i.e. B cells (Figure 6A).  CD21 and CD23 were used in Study I and II to 
separate the CD21+ and CD21-/low cells (Figure 6A). After Study I and II, we 
found that for our purposes it was not necessary to use CD23 in the definition 
of the cells. Therefore, in Study III we decided to exclude CD23 and analyze 
the cells based on their expression levels of CD21, i.e. as CD21+ or CD21low/-. 
The CD21+ and CD21l/low cells were gated on separately using either CD38 
vs. CD24 (Figure 6B) 163, 164 or the IgD vs. CD27 (Figure 6C) 164 strategy for 
subpopulations.  
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Figure 6. Gating strategies used in Studies I-III. A. Shows gating from 
lymphocytes to CD21+ vs. CD21-/low cells. Further gating of the CD21+ vs. CD21-
/low cells is shown in B and C, where schematics and FACS plots are shown for B. 
CD38 vs. CD24 gating strategy and C. IgD vs. CD27 gating strategy.  Sample 
from HD.  
The CD38 vs. CD24 gating separates: Transitional (CD38++CD24++), naive 
(CD38+CD24+), MBCs (CD38+ that are either CD24+ or CD24low) and 
plasmablasts (CD38++CD24-).  
The IgD vs. CD27 gating separates the transitional and naive (CD27-IgD+), 
unswitched MBCs (CD27+IgD+), switched MBCs (CD27+IgD-) and DN 
MBCs (CD27-IgD-). 
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3.3.3 CELL SORTING (STUDY I) 
Flow cytometry was also used for B cell sorting where we isolated 
CD21+CD27- (CD21+ naive and transitional cells) and CD21+ CD27+ (CD21+ 
MBCs) and CD21-/low cells. First B cells were purified from PBMCs using 
immunomagnetic beads (purity 99%). The B cells were then stained with 
antibodies recognizing CD19+, CD27+ and CD21+ and sorted on a Synergy 
cell sorter (purity >95%). 
3.3.4 CD69 UPREGULATION ON CELL SURFACE 
(STUDY I) 
We cultured PBMCs or B cells (purified as described in section 3.3.3) in 96-
well plates and stimulated with the following single stimuli: TLR7/8 agonist 
(R848), TLR9 agonist (CpG), BCR agonist (anti-human IgA/IgG/IgM 
F(ab')2) and IL-2. CD69 upregulation was assessed after 3 h by flow 
cytometry. 
3.3.5 PROLIFERATION AND DIFFERENTIATION OF 
B CELLS AND SUBPOPULATIONS (STUDY I) 
Total B cells or subpopulations (purified as described in section 3.3.3) were 
labeled with CellTrace Violet Cell Proliferation Kit and cultured in 96 well 
plates. The cells were stimulated with different combinations of the stimuli 
used in 3.3.4: TLR7/8 agonist, TLR9 agonist, BCR agonist and IL-2. We 
assessed cell proliferation and plasmablast differentiation at day 5 by flow 
cytometry. 
3.3.6 CHEMOKINE ANALYSIS (STUDY II) 
To study the migration pattern of the synovial B cells the following 
chemokines were analyzed: CXCL-9, CXCL-10 and CXCL-11 in SF and 
blood plasma of patients with RA (Table 7). Analysis of the chemokines was 
performed using cytometry bead-based immunoassay (LEGENDplex™ 
Human Proinflammatory Chemokine Panel, BioLegend) according to the 
manufacturer's instructions. Samples were acquired with a FACSVerse 
equipped with FACSuite software (BD Bioscience, San Jose, USA) and 
analyzed by FCAP Array software (Soft Flow, Pecs; Hungary). Plasma and 
SF were diluted 1:2 in PBS and treated with heteroblock (HeteroBlock®, 
Omega Biologicals, USA) before analysis. 
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3.3.7 ELISA ANALYSIS OF RANKL/OPG (STUDY II) 
Concentrations of osteoprotegerin (OPG) and RANKL in plasma and SF 
were measured using ELISA kits according to the manufacturer's instructions 
(Human Osteoprotegerin/TNFRSF11B Duoset ELISA, Human 
TRANCE/RANKL/TNFSF11 Duoset ELISA, R&D Systems, USA). Plasma 
and SF of patients (Table 7) were diluted 1:2 in PBS and treated with 
heteroblock (HeteroBlock®, Omega Biologicals, USA) before analysis. 
3.3.8 STATISTICAL ANALYSIS (STUDY I-III) 
Study I: Graph-Pad Prism version 6 was used for statistical analyses. 
Comparisons between two groups was analyzed using unpaired Mann-
Whitney test and between >2 groups one-way analysis of variance (ANOVA) 
was used followed by Dunnett's multiple comparison test. P<0.05 was 
considered significant. 
Study II: Comparisons of B cell populations in patients and HDs were 
compared using a two-tailed Mann-Whitney test or Kruskal-Wallis test. 
P<0.05 was considered significant. The correlations between B cell 
subpopulations and clinical factors were calculated using Spearman’s rank 
test. In this explorative study we decided against applying multiple 
significance test such as Bonferroni as it would reduce the chance of type I 
error at the expense of type II error 165. Statistical analyses were performed 
using GraphPadPrism version 7 and IBM SPSS Statistics version 23. 
Study III: In large data set, multivariate factor analysis (SIMCA) can be 
applied to reveal patterns and relations between the analyzed factors. To 
investigate the associations between B cell subpopulation proportions (X-
variables) and clinical diagnosis of RA (Y-variable) or clinical parameters 
(Y-variables) multivariate factor analysis (SIMCA-P+ software; Umetrics, 
Umeå, Sweden) was used. To investigate whether patients could be 
discriminated from HDs based on the various X-variables i.e. B cell 
populations, orthogonal projections to latent structures discriminant analysis 
(OPLS-DA) was used. VIP (variable importance for projection) values were 
used to identify X-variables that associated most strongly with the respective 
Y variable. When examining associations between a Y-variable (clinical 
parameters such as DAS28) and X-variables (B-cell populations) orthogonal 
projections to latent structures by means of partial least squares (OPLS) was 
used. Data was normalized using log transformation. In the analyses the 
column bars represent the importance of each X-variable to the Y-variable, 
i.e. the larger the bar is the stronger the contribution to the model is. The 
error bar represents the certainty of the contribution. The quality of the OPLS 
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models was assessed based on the parameters R2 (i.e., how well the variation 
of the variables is explained by the model), and Q2 (i.e., how well a variable 
can be predicted by the model).   
Univariate analysis of B cell populations between groups was performed with 
a two-tailed Mann-Whitney test for comparisons of two groups and a 
Kruskal-Wallis test for comparisons of three groups (IBM SPSS Statistics 
version 23). For correlation analysis, a two-tailed Spearman’s Rank 
correlation test was used (IBM SPSS Statistics version 23). A P<0.05 was 
considered statistically significant. Linear regression was used to adjust for 
age when looking at the association between CD21+ DN and TJC28 as well as 
CD21-DN and joint narrowing score. 
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4 RESULTS AND DISCUSSION 
4.1 STUDY I: CD21-/LOW B CELLS IN HUMAN 
BLOOD ARE MEMORY CELLS 
A study had reported that cells lacking CD21 and CD23, CD21-/low cells were 
autoreactive in SLC-/- mice but not in control mice 94. In translational effort, 
we set out to determine whether we could define a similar B cell 
subpopulation in humans. In Study I we looked at the CD21-/low subset in cord 
blood and adult peripheral blood, characterizing a CD21-CD23- population, 
which we defined as the CD21-/low population. We also asked which B cell 
population these cells belonged to e.g. naive or MBCs (Figure 7).  
 
Figure 7. Main B cell populations in human peripheral blood: Transitional, naive 
and MBCs and plasmablasts/plasma cells. Typical cell surface markers are 
shown. Some plasmablasts/plasma cells express CD19 whereas others have low 
levels or lack CD19 92. ABCB1 tr., ABCB1 transporter.  
When we looked at CD21-/low cells in peripheral blood of adults and cord 
blood we found large differences. The CD21-/low cells in cord blood were 
primarily CD10+ transitional cells but only 10% of the CD21-/low population 
in adults belonged to the transitional compartment. In fact, after excluding 
CD10+ cells i.e. transitional cells, a CD21-/low population was barely 
detectable in cord blood but comprised around 5% of the B cells in peripheral 
blood from adults (both in 24-30 and 55-64 years olds). This was in 
accordance with previous studies that show that MBCs are rare in the blood 
of infants until 2 years of age 166. This also suggested that the CD21-/low cells 
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seen in adults were not transitional cells but belonging to a more mature B 
cell population.  
We did not exclude transitional cells from further experiments, as they were 
so few amongst the CD21-/low cells. When we used the classical memory 
marker CD27 88 we found that it was expressed by only 30% of CD21-/low 
cells in peripheral blood. This would indicate that the cells were mainly 
naive. However, 75% of CD21-/low cells in tonsils expressed CD27, thus 
indicating memory cells. To further delineate the phenotype we used multiple 
markers to characterize the phenotype and we also included tonsils for 
comparison. When we used the CD38 and CD24 gating strategy we found 
that the CD21-/low cells in adult peripheral blood were primarily CD38- (85%), 
which indicated a memory cell population rather than naive B cell or 
plasmablasts (Figure 8).  
Figure 8. Gating strategy CD38 vs. CD24 is shown in the schematics. 
Representative samples from cord blood, adult peripheral blood (PBMCs) and 
tonsils are depicted. GCs, germinal center B cells. 
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Of the CD21-/low cells in peripheral blood around 15% were IgM+IgDdim, 17% 
IgG+ and 9% IgA+ % consistent with not being naive B cells. However, as 
there was still a large proportion that was IgM+IgD+ we wanted to see 
whether we could exclude the possibility that the CD21-/low cells belonged to 
naive cells. For this purpose we used expression of the marker ABCB1 
transporter as it is only expressed on naive cells 167, and found that CD21-/low 
cells lacked the transporter. In addition, we found that the CD21-/low cells 
resembled MBCs more than naive cells (CD21+CD27+ and CD21+CD27- 
respectively) when analyzing their expression of activation markers i.e. CD80 
and CD95. The CD21-/low cells also showed an increased downregulation of 
CD62L compared to naive cells and MBCs, indicating previous activation. 
Taken together the phenotype of the CD21-/low cells using multiple markers 
indicated that they were mainly MBCs.  
Next we wanted to investigate whether the CD21-/low cells behaved similar to 
MBCs. Planning this experiment, we anticipated that the cells would be less 
responsive to BCR stimuli because the lack of CD21 would probably raise 
the activation threshold for BCR activation. However, we were unsure how 
the CD21-/low cells would respond to other stimuli i.e. TLR agonists and 
cytokines. For this purpose we stimulated the cells in vitro with a single 
stimuli: 
• IL-2 or,  
• BCR agonist or, 
• TLR7/8 agonist or,   
• TLR9 agonist or, 
 
We then measured the upregulation of CD69 on the cell surface as it is one 
of the earliest inducible leucocyte activation markers (3 hours) 168. Again, we 
compared the CD21-/low cells to the CD21+ naive and CD21+ MBCs and 
found that the CD21-/low cells did not respond as well as the other populations 
to the stimuli (except for IL-2 single stimuli where none of the cell 
populations responded) (Figure 9). Our previous analysis of the CD21-/low 
cells phenotype had revealed that the CD38- could be divided into two 
groups, CD24+ and CD24low, where the CD24+ cells were enriched for IgM+ 
IgD+ cells and the CD24low cells for IgM-IgD- cells. This difference in 
phenotype was also reflected in their response, as mainly the CD38- CD24low 
subpopulation was unresponsiveness to any of the single stimuli (Figure 9). 
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Figure 9. Expression of CD69 upon single stimuli is shown for CD21+ naive and 
memory cells and the CD24+ and CD24low subsets of CD21-/low CD38- cells. R848, 
TLR7/8 agonist; CpG, TLR9 agonist. 
However, we had so far only used single stimuli and our measurement of 
response was only the upregulation of the CD69 marker. This did not tell us 
anything about the CD21-/low cells ability to proliferate and differentiate upon 
stimulation. We decided to test that in our next experiment. For stimulation, 
we chose to use the combination of IL-2 and a TLR7/8-agonist as it had 
induced the highest level of proliferation in total B cells. We sorted the cells 
into the following subpopulations CD21+CD27+, CD21+CD27- and CD21-/low 
cells before stimulation and culture for five days. The sorting was necessary 
as stimulation of the B cells for longer periods of time (as in this experiment) 
leads to downregulation of CD21 on all B cells, hence we would not be able 
to electronically gate on CD21-positive and negative cells 169. It is known that 
MBCs respond with proliferation and differentiation to TLR agonists without 
any BCR stimulation but that the naive B cells need BCR stimulation as well 
170. Our results showed that the naive cells did not proliferate upon IL-2 and 
TLR7/8 agonist stimulation whereas a similar proportion of both CD21+ 
MBCs and CD21-/low cells proliferated (88% and 75%, respectively) (Figure 
10A, upper row). This strongly suggested that the CD21-/low cells were 
MBCs. Further addition of a BCR agonist induced proliferation of all three 
cell populations: CD21+ naive and MBCs and CD21-/low cells (Figure 10B, 
upper and middle row). Again the response of CD21-/low cells was very 
similar to the MBCs but not to the naive cells (Figure 10B, upper and middle 
row). We also looked at the cells ability to differentiate in response to 
aforementioned combination stimuli. Fewer than 5% of naive cells 
differentiated after stimulation with either stimuli combination (Figure 10A 
and B, bottom row). Stimulating with IL-2 and TLR7/8 agonist induced 
around 20% of CD21+ MBCs and 10% of CD21-/low B cells to differentiate 
(Figure 10A, bottom row). Adding the BCR agonist to the stimuli increased 
the proportion differentiated in both CD21+ MBCs and CD21-/low cells to 
around 40% (Figure 10B, bottom row). Our conclusion was that the CD21-/low 
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cells belong to the memory compartment based on their phenotype and 
response to stimuli. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Proliferation and differentiation of B cell subpopulations upon stimuli 
with A. TLR7/8-agonist (R848) and IL-2. B. TLR-7/8 agonist, BCR-agonist and 
IL-2. Upper row demonstrates proliferation as a proportion of the maximum 
proliferation, middle row the absolute cell numbers. Bottom row shows the 
proportion of cells that has differentiated into plasmablasts (CD27++CD38++)  
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4.2 STUDY II: CD21-/LOW B CELLS ASSOCIATE 
WITH JOINT DAMAGE IN RHEUMATOID 
ARTHRITIS PATIENTS 
Our results in Study I demonstrated the presence of a CD21-/low cell 
population in HDs. We thereafter set out to investigate the CD21-/low cells in 
autoimmune disease because of the findings that the CD21-/low cells in the 
SLC-/- mouse model but not in the control mice were autoreactive 94. We 
chose to look in patients with RA because the disease is well defined in terms 
of disease activity and severity. We divided the RA patients into two groups 
based on the presence or absence of autoantibodies (ACPA and RF) and 
analyzed their B cell populations (Gating strategy is shown in Figure 11).  
Figure 11. Gating strategy of B cell subpopulations is shown. A. First we gated on 
PBMCs for lymphocytes, then singlets and further CD19+ B cells. After dividing B 
cells into CD21+ and CD21-/low subsets, two main gating strategies were used: B. 
The CD38 and CD24 gating strategy C. The IgD and CD27 gating strategy.  
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There were no significant differences in the absolute numbers and 
proportions of CD21-/low B cells between the two RA patient groups and the 
HDs. Just as we had seen for HDs in Study I the phenotype of the CD21-/low 
cells in RA patients indicated that they were mainly MBCs as around 70% 
were CD38- and approx. 80% were either CD27+ or CD27-IgD-. Additionally 
there was an overlap between the differentially defined memory 
subpopulations, such that 55% of the CD21-/lowCD38-CD24low cells were also 
IgD-CD27- (CD21-/low DN MBCs). The proportion of these two MBC 
populations CD21-/low CD38-CD24low and CD21-/low DN were elevated in 
ACPA/RF positive patients relative to HDs. Differences between the 
ACPA/RF negative patients and HDs were not statistically significant. 
Next we wanted to investigate whether these B cell subpopulations were 
associated with clinical parameters. We did not find any association between 
the different subpopulations and disease activity. However, it should be noted 
that the patients had mainly low-active disease so we were unable to compare 
low-activity versus high-activity. We found no correlations with disease 
duration or treatment (including present or previous TNF inhibitory therapy). 
Here it should also be taken into account that the groups were small. It is 
known that ACPA/RF positive patients have worse prognosis than ACPA/RF 
negative patients with an increased risk of developing joint erosions and 
deformities. As expected, joint destruction (measured by modified Sharp van 
der Heijde score (mSHS)) was greater in ACPA/RF positive patients than in 
ACPA/RF negative patients (median scores were 25 (IQR 12-35) and 15 
(IQR 12-17) respectively). mSHS is a composite score combining an erosion 
score, quantifying bone loss and a joint narrowing score, measuring cartilage 
destruction. The ACPA/RF positive patients were divided into two groups at 
the median mSHS to produce Low mSHS (<20) and High mSHS (≥20). The 
proportion of CD21-/low B cells between the two groups showed that the 
CD21-/low DN population in patients with High mSHS was significantly 
expanded relative to the same population in both Low mSHS patients and 
HDs (Figure 12A). Moreover, the frequency of the CD21-/low DN MBCs was 
positively and significantly correlated with mSHS in ACPA/RF positive 
patients (Figure 12B). The erosion score is characteristic of RA but the joint 
narrowing score, i.e. the breakdown of cartilage, can be attributed to other 
causes than RA, such as osteoarthritis. Separating the two components of 
mSHS showed that the greater contribution to joint damage was derived from 
the erosion score for which the positive correlation with the CD21-/low DN 
population approached statistical significance, whereas the joint narrowing 
score did not (Figure 12C and data not shown). We interpreted our findings 
as a link between expansion of the CD21-/low DN MBC population and 
erosive joint damage in RA.   
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Figure 12. CD21-/low DN cells associate with joint damage. A. Proportion of 
CD21-/low DN in ACPA/RF positive RA patients with High mSHS ( ≥20 ) and Low 
mSHS (<20) as well as HDs. B-C. Correlation of the frequency of CD21-/low DN in 
ACPA/RF positive RA patients and B. total mSHS and C. Erosion score. D. CD21-
/low DN cells express CXCR3 that indicates homing to inflammatory sites. E-F. 
CD21-/low DN cells are enriched in SF. G-I. CD21-/low DN express G. FcRL4 H. 
CD11c and I. RANKL  
The next question we asked was whether any of the B cells recruited to the 
target organ, i.e. the joint, was CD21-/low and, if so, whether they were DN. In 
SF, we found that around 80% of the B cells were CD21-/low and that around 
half of these cells expressed CXCR3 supporting homing to inflammatory 
sites (Figure 12D). CXCR3 was also expressed on approximately half of the 
CD21+ cells in SF (Figure 12D). Additionally, the CD21-/low cells in SF were 
mainly composed of DN and switched MBCs (Figure 12E and F).  
A marker that has been associated with the CD21-/low cells is CD11c 171. 
There were large differences in the expression of CD11c between CD21+ and 
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CD21-/low cells. In blood it was barely detectable on CD21+ cells whereas 
around 35% of the CD21-/low cells were CD11c+ (Figure 12G). This 
difference became more pronounced in the SF, where the vast majority of the 
CD21-/low cells were CD11c+ (including the DN) and around one third of the 
CD21+ cells.  
RANKL is essential for osteoclastogenesis, which leads to breakdown of 
bone and can thus contribute to joint destruction 172. An FcRL4+ B cell 
population expressing RANKL+ has been described in synovial tissue and 
fluid from RA patients 160. We found that few B cells in blood expressed 
FcRL4, which is in line with previous studies demonstrating that FcRL4+ 
cells are found in tissues but are scarce in blood 102. Furthermore, around 
40% of the CD21-/low B cells in SF were FcRL4+ and these were concentrated 
in the DN memory population of which around half were FcRL4+ (Figure 
12H). We also investigated whether the CD21-/low DN cells could possibly 
influence joint erosions and looked at their expression of RANKL. There was 
no detectable expression of RANKL on any B cell subpopulation in blood 
(data not shown), whereas around 30% of the CD21-/low DN cells and 20% of 
the switched MBCs (CD27+IgD-) in SF expressed RANKL (Figure 12I). The 
ratio of soluble RANKL/Osteoprotegerin (RANKL/OPG) can be used as a 
measure of the potential for bone erosion 173, 174. We measured this ratio in 
blood and SF and found that it was constant for all subjects ruling out soluble 
RANKL as an agent for bone damage in RA.   
In conclusion, the CD21-/low DN MBCs in ACPA/RF positive patients 
associate with joint damage based on its higher proportions in patients with 
higher mSHS score compared to those with lower scores. In addition the 
frequency of CD21-/low DN cells correlated with mSHS. This population is 
enriched in SF of RA patients and likely overlaps with previously described 
FcRL4+ cells in SF. The CD21-/low DN MBCs express RANKL, further 
linking these cells to joint destruction.   
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4.3 STUDY III: MEMORY B CELL SUBSETS 
CORRELATE WITH AUTOANTIBODY 
TITERS, DISEASE ACTIVITY AND JOINT 
DAMAGE IN UNTREATED EARLY 
RHEUMATOID ARTHRITIS 
In study II, we investigated RA patients with established RA, under treatment 
and with low disease activity. In Study III, we studied B cell populations in a 
cohort of untreated early RA (ueRA) patients. The advantages of studying 
untreated patients were that the patients had highly active RA and differences 
in B cell populations between ueRA patients and HDs could not be due to the 
effect of treatments. Thus, differences in B cell populations between patients 
and HDs would potentially be more clear and robust.  
Analysis of the B cell subpopulations was done similarly to study II, where 
we utilized two main gating strategies i.e. CD38 vs. CD24 and IgD vs. CD27. 
For defining the CD21-/low cells we only used CD21 and not CD23, as it was 
now clear from Study I-II that CD21-/low could be defined without using 
CD23. This also allowed us to use other markers in its place that would 
provide more information, e.g. IgM and IgG for isotypes. Analysis using the 
aforementioned gating strategies generated many different B cell subsets, so 
in order to see whether any specific B cell population associated with RA 
and/or clinical parameters, we applied multivariate analysis. Age and gender 
were included in the analysis as possible confounders but did not affect the 
results. We found that the CD21+ B cell populations with the strongest 
positive associations to untreated early RA (ueRA) were the naive and 
transitional cells, gated either as CD27-IgD+ (naive and transitional cells) or 
CD38+CD24+ (naive only cells) (Figure 13A). The strongest negative 
association to ueRA was with the MBCs (CD38-CD24+), both unswitched 
(CD27+IgD+) and switched (CD27+IgD-) MBCs. These associations were 
confirmed with univariate analyses (Figure 13B-E and data now shown). The 
decrease of MBCs seen here in ueRA is also observed in other autoimmune 
diseases 175-177. What this decrease stands for is currently unknown but it 
could be due to MBCs leaving the circulation and homing to inflamed tissues 
e.g. the joints in RA. Unfortunately we did not have smoking data for the 
HDs so we could not include smoking in the analysis.  
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Figure 13. B cell populations in ueRA patients and HDs. A. Plot shows 
associations between B cell populations in ueRA patients and HDs using 
multivariate analysis. Stars indicate significant differences between the two 
groups using univariate analysis. In B.-E. univariate analysis was used to 
compare the frequencies of B. CD21+ naive and transitional cells (CD27-IgD+), 
C. CD21-/low DN (CD27-IgD-) MBCs, D. CD21+ unswitched (CD27+IgD+) MBCs 
and E. CD21+ switched (CD27+IgD-) MBCs between ueRA patients and HDs. 
Line represents median. Mann-Whitney test. *<0.05, **<0.01, ***<0.001, 
****<0.0001.  
Because we had found in study II that the CD21-/low DN (CD27-IgD-) 
population in patients with established RA was enriched in the inflamed 
joints and that this population correlated with the joint destruction, we were 
interested in its association also to ueRA. Unlike the unswitched and 
switched CD21+ MBC populations, which were reduced in ueRA, we found a 
positive association between ueRA and CD21- DN MBCs that was confirmed 
in univariate analysis (Figure 13 A and C).  
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Our next question was whether the CD21+ naive and transitional B cells were 
associated with disease activity. Using multivariate analyses, we saw a 
possible effect of smoking (Figure 14A), which was confirmed in univariate 
analysis (Kruskal-Wallis test) comparing the proportions of CD21+ naive and 
transitional B cells in current, ex-smokers and non-smokers (74%, 75% vs. 
83% respectively, with p=0.03). We therefore looked at the disease activity 
separately in these two groups of patients i.e. non-smokers and current/ex- 
smokers. In non-smokers, there was a negative correlation between the 
frequency of CD21+ naive and transitional cells and disease activity measured 
by DAS28-CRP and TJC28, i.e. the higher the frequency of these B cells the 
lower the disease activity (Figure 14B and C). No significant correlations 
were found in RA patients that were ex-/current smokers.  
Figure 14. The association between CD21+ naive and transitional cells and 
clinical disease activity in RA patients. A. Multivariate analysis demonstrated 
association between CD27-IgD+ cells and smoking as well as disease activity that 
was confirmed in univariate analysis B-C. (Spearman test). *<0.05, 
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This observation raised the question of whether there might be a 
correspondingly higher frequency of a specific memory B cells population 
correlating to disease activity. We found that the CD21+ DN population was 
associated the clinical factors CDAI, DAS28-ESR, DAS28-CRP, SJC28, 
TJC28 as well as age (Figure 15A) and univariate analysis confirmed a 
positive correlation between CD21+ DN and TJC28 (Figure 15B) that 
remained significant after adjusting for age with linear regression.  
Keeping in mind our previous results from study II, where we revealed a 
possible role for CD21-/low DN B cells in joint damage in RA patients with 
established disease, we investigated a potential association with clinical 
parameters in ueRA. Using multivariate analyses, we found that CD21-/low 
DN cells were positively associated with joint narrowing score (JNS), total 
erosion score (mSHS) and age, as well as negatively associated with TJC28 
and ACPA titers (Figure 15C). After adjusting for age, a significant positive 
correlation between frequency of CD21-/low DN cells and joint narrowing 
score remained (Figure 15D), linking the enhanced presence of this B cell 
population with joint damage.  
Smoking seemed to influence our multivariate models of CD27+ MBCs and 
this was confirmed in a univariate analysis for CD21+CD27+ unswitched 
MBCs comparing non-smokers vs. ex/current smokers (2 % vs. 4 % 
respectively, p<0.05). Therefore, to look at whether there were differences in 
CD27+ MBCs depending on autoantibody status we looked separately in non-
smokers and ex-/current smokers. As almost all of the ex-/current smokers 
were RF and/or ACPA positive we could only investigate the effect of 
autoantibody status in non-smokers. We found significantly higher 
frequencies of CD21+ switched MBCs in ACPA/RF positive non-smoking 
ueRA patients compared to ACPA/RF negative RA (7% vs. 4%, p =0.035).  
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Figure 15. Figure shows the associations found in study III between B cell 
populations and measures of disease activity, severity and autoantibodies. 
Few studies have shown correlations between B cell populations and 
autoantibody titers. In this study we found that in non-smokers, but not ex-
/current smokers, there was a positive correlation between CD21+ switched 
MBCs and both ACPA and RF titer (Figure 15E and F) and between CD21+ 
unswitched MBCs and RF titer (Figure 15G) linking both switched and 
unswitched MBCs to the autoantibody production. Possible mechanism 
behind these associations could be that in RA a proportion of the CD21+ 
unswitched MBCs becomes IgM+IgD+ plasmablasts secreting RF (which is 
mainly IgM) and additionally, a proportion of the CD21+ switched MBCs 
becomes IgM+ plasmablasts secreting RF or IgG+ plasmablasts secreting 
ACPA (which is mainly IgG).  
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5 CONCLUSION 
The main findings in the thesis are as follows: 
• The CD21-/low B cell population is mainly MBCs both in HDs 
and RA patients. Similar to other CD21-/low populations 
described in autoimmune disease, the CD21-/low DN MBCs 
express CD11c and FcRL4. However, in the other diseases they 
are not necessarily DN i.e. CD27-IgD-.  
• In ueRA patients we conclude that the CD21+ DN B cells play a 
role in joint inflammation and the CD21+ CD27+ MBCs in 
autoantibody production. These conclusions are based on our 
findings that these cell populations correlated positively with 
tender joint count and with autoantibody titers respectively. 
• Smoking is associated with an increase in the proportion of 
CD27+ MBCs suggesting that it affects the memory population 
of B cells. An observation that suggests that smoking should be 
taken into account when designing B cell studies. 
• The main conclusion is that CD21-/low DN MBC population may 
contain pathogenic clones that lead to joint damage via 
RANK/RANKL interactions. This is supported by our findings 
that: 
o  CD21-/low DN MBCs are increased in ACPA/RF positive 
patients with established RA compared to HDs. 
Furthermore, they are increased in ACPA/RF positive RA 
patients with more joint destruction compared to those with 
less. Moreover, the CD21-/low DN MBCs correlated 
positively with the level of joint destruction. 
o CD21-/low DN MBCs express a homing marker i.e. CXCR3 
for inflammatory sites and are greatly enriched in the joints 
of RA patients.  
o In the inflamed RA joint, a third of the CD21-/low DN MBCs 
express RANKL further tying them to joint erosions as 
RANKL stimulates the maturation of osteoclasts, which 
leads to bone erosions. 
o In ueRA the CD21-/low DN MBCs correlated positively with 
joint narrowing score. 
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6 FUTURE PERSPECTIVES 
Our main findings suggest that different B cell populations are associated 
with disease activity, disease severity and autoantibodies in RA patients.  
In early RA patients the next step is to see whether the correlations we have 
seen continue after the start of therapy. Do the CD21+CD27+ MBCs follow 
changes in autoantibody titers? Do the DN cell populations associate with 
joint damage and inflammation in the patients after 1 year? After 2 years? 
Another important question is whether any of these B cell populations can 
predict treatment response to biologic therapy and whether the B cell 
populations can differentiate between the different treatments, e.g. patients 
that have a high frequency of DN B cells should receive treatment X instead 
of treatment Y.  
We want to look further at the function of the CD21-/low cells in RA patients 
and to see whether they respond differently to stimuli than CD21-/low cells in 
HDs. It would be interesting to test the different combination of TLR7/TLR9 
agonists, BCR agonists and IL-2, as well as other cytokines. What would also 
provide more clues about the role of CD21-/low cells is information about what 
they secrete upon stimuli i.e. pro-inflammatory cytokines, anti-inflammatory 
cytokines, autoantibodies or RANKL. It would also be important investigate 
whether the CD21-/low cells in peripheral blood migrate to the inflamed joints. 
This could be done indirectly by looking at the B cell clones in peripheral 
blood and joints and see if any clones are shared between the two 
compartments.  
The new cancer treatment with checkpoint inhibitors gives a new insight into 
the triggering of autoimmunity. We would like to study the B cell 
populations, especially the CD21-/low population in these patients, and to see 
whether any specific B cell population could predict treatment response. It 
would also be interesting to investigate whether any B cell population could 
predict the type of reaction the patients develop e.g. arthritis versus gut 
inflammation.   
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